Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1231-1240 Newer>

BusinessWeek June 21, 2004 Catherine Arnst	Cancer Superdrugs, Costly Side Effects New therapies are extending lives, but the prices could weigh down the nation. Oncologists, pharmaceutical companies, and the government will have to focus on the best way to lower prices for these drugs.
Registered Rep. June 1, 2004 Bob Hirschfeld	The Virtue of Moderation With American obesity at epidemic proportions, diet products and weight-loss drugs are popular fare. However, many of the most promising obesity-control drugs await federal approval.
The Motley Fool June 7, 2004 Brian Gorman	Novartis Nabs Sabex Novartis' purchase gives it a lifeline to the generics market.
The Motley Fool June 4, 2004 Roger Nusbaum	IDEXX Labs a Boring Biotech? IDEXX Laboratories is one of those boring companies you've probably never heard of but in hindsight wish you had owned.
BusinessWeek June 14, 2004 Gene G. Marcial	From Pain Therapeutics: A Better Pain Killer Remoxy, now in proof-of-concept trials, could become the replacement for the most popular opioid pain killer OxyContin, with a potential $1 billion market.
The Motley Fool June 3, 2004 Charly Travers	Small Drug Market, Big Hopes BioMarin is going to file for approval in the U.S. and Europe in the fourth quarter of this year after its succesful phase 3 trial of Aryplase. If the drug is approved, it would likely be on the market toward the end of 2005.
The Motley Fool June 3, 2004 Charly Travers	New Chapter for Indevus The drug company Indevus puts troubled history behind it with the launch of the drug Sanctura which is now on the market for the treatment of overactive bladder.
The Motley Fool June 3, 2004 Brian Gorman	Spitzer Chases Glaxo Did the drug company GlaxoSmithKline withhold information about the effects of Paxil in children? No doubt the bad publicity will continue to hit the stock.
The Motley Fool June 2, 2004 W.D. Crotty	FDA's Kiss of Life The FDA ignores its advisory committee and approves Allos' new drug.
The Motley Fool June 2, 2004 Roger Nusbaum	POZEN Is a Poser Here's a great example of the riskiest type of biotech stock.
<Older 1231-1240 Newer> Return to current articles.